Abstract

Tintu C. Sunny*, Rosmin Jacob, K. Krishnakumar and Carolin Antony

ABSTRACT

Anticoagulants are the cornerstone therapy for many thromboembolic diseases. Theses drugs bring their action by reduce the rate of fiber in formation and indicated to prevent thrombus extension and embolic complications. Traditionally, heparin is given as parenteral anticoagulant, whereas warfarin is given as oral anticoagulant. In the last several years, 4 noval oral anticoagulants are approved by FDA includes dabigatran (2010), rivaroxaban (2011), apixaban (2012) and edoxaban (2015). In Randomized clinical trials and observational studies shows that the efficacy and safety of DOACs for stroke prevention in patients with atrial fibrillation have been shown to be comparable or superior to warfarin. Clinical development paves way for the emergence of novel oral anticoagulants. Because of their ease of use and favorable pharmacodynamic profile, the older agents are replaced by the newer ones. However, these agents are not free of adverse events. Hemorrhage is most commonly occurring adverse event. When taken into consideration the overall OAC utilization pattern remained steady. In the starting of 2010, there is a gradual decrease in warfarin use with corresponding increase in the use of direct oral anticoagulants.